Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced publication of data that demonstrates the use of the Company's zinc finger DNA-binding protein (ZFP) technology to achieve highly efficient, permanent correction of a disease-causing gene in primary human cells. This research, published in Nature as an advance online publication, represents a significant advance in the ability to [...]